2025-01-162026-06-302026-06-30false16189449TAFFS PHARMACY BRIGG LIMITED2026-10-16falseiso4217:GBPxbrli:pure161894492025-01-15161894492026-06-30161894492025-01-162026-06-30161894492025-01-14161894492025-01-15161894492025-01-152025-01-1516189449bus:SmallEntities2025-01-162026-06-3016189449bus:AuditExempt-NoAccountantsReport2025-01-162026-06-3016189449bus:FullAccounts2025-01-162026-06-3016189449bus:PrivateLimitedCompanyLtd2025-01-162026-06-3016189449core:WithinOneYear2026-06-3016189449core:AfterOneYear2026-06-3016189449core:WithinOneYear2025-01-1516189449core:AfterOneYear2025-01-1516189449core:ShareCapital2026-06-3016189449core:SharePremium2026-06-3016189449core:RevaluationReserve2026-06-3016189449core:OtherReservesSubtotal2026-06-3016189449core:RetainedEarningsAccumulatedLosses2026-06-3016189449core:ShareCapital2025-01-1516189449core:SharePremium2025-01-1516189449core:RevaluationReserve2025-01-1516189449core:OtherReservesSubtotal2025-01-1516189449core:RetainedEarningsAccumulatedLosses2025-01-1516189449core:LandBuildings2026-06-3016189449core:PlantMachinery2026-06-3016189449core:Vehicles2026-06-3016189449core:FurnitureFittings2026-06-3016189449core:OfficeEquipment2026-06-3016189449core:NetGoodwill2026-06-3016189449core:IntangibleAssetsOtherThanGoodwill2026-06-3016189449core:ListedExchangeTraded2026-06-3016189449core:UnlistedNon-exchangeTraded2026-06-3016189449core:LandBuildings2025-01-1516189449core:PlantMachinery2025-01-1516189449core:Vehicles2025-01-1516189449core:FurnitureFittings2025-01-1516189449core:OfficeEquipment2025-01-1516189449core:NetGoodwill2025-01-1516189449core:IntangibleAssetsOtherThanGoodwill2025-01-1516189449core:ListedExchangeTraded2025-01-1516189449core:UnlistedNon-exchangeTraded2025-01-1516189449core:LandBuildings2025-01-162026-06-3016189449core:PlantMachinery2025-01-162026-06-3016189449core:Vehicles2025-01-162026-06-3016189449core:FurnitureFittings2025-01-162026-06-3016189449core:OfficeEquipment2025-01-162026-06-3016189449core:NetGoodwill2025-01-162026-06-3016189449core:IntangibleAssetsOtherThanGoodwill2025-01-162026-06-3016189449core:ListedExchangeTraded2025-01-162026-06-3016189449core:UnlistedNon-exchangeTraded2025-01-162026-06-3016189449core:MoreThanFiveYears2025-01-162026-06-3016189449core:Non-currentFinancialInstruments2026-06-3016189449core:Non-currentFinancialInstruments2025-01-1516189449dpl:CostSales2025-01-162026-06-3016189449dpl:DistributionCosts2025-01-162026-06-3016189449core:LandBuildings2025-01-162026-06-3016189449core:PlantMachinery2025-01-162026-06-3016189449core:Vehicles2025-01-162026-06-3016189449core:FurnitureFittings2025-01-162026-06-3016189449core:OfficeEquipment2025-01-162026-06-3016189449dpl:AdministrativeExpenses2025-01-162026-06-3016189449core:NetGoodwill2025-01-162026-06-3016189449core:IntangibleAssetsOtherThanGoodwill2025-01-162026-06-3016189449dpl:GroupUndertakings2025-01-162026-06-3016189449dpl:ParticipatingInterests2025-01-162026-06-3016189449dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-162026-06-3016189449core:ListedExchangeTraded2025-01-162026-06-3016189449dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-162026-06-3016189449core:UnlistedNon-exchangeTraded2025-01-162026-06-3016189449dpl:CostSales2025-01-152025-01-1516189449dpl:DistributionCosts2025-01-152025-01-1516189449core:LandBuildings2025-01-152025-01-1516189449core:PlantMachinery2025-01-152025-01-1516189449core:Vehicles2025-01-152025-01-1516189449core:FurnitureFittings2025-01-152025-01-1516189449core:OfficeEquipment2025-01-152025-01-1516189449dpl:AdministrativeExpenses2025-01-152025-01-1516189449core:NetGoodwill2025-01-152025-01-1516189449core:IntangibleAssetsOtherThanGoodwill2025-01-152025-01-1516189449dpl:GroupUndertakings2025-01-152025-01-1516189449dpl:ParticipatingInterests2025-01-152025-01-1516189449dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-152025-01-1516189449core:ListedExchangeTraded2025-01-152025-01-1516189449dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-152025-01-1516189449core:UnlistedNon-exchangeTraded2025-01-152025-01-1516189449core:NetGoodwill2026-06-3016189449core:IntangibleAssetsOtherThanGoodwill2026-06-3016189449core:LandBuildings2026-06-3016189449core:PlantMachinery2026-06-3016189449core:Vehicles2026-06-3016189449core:FurnitureFittings2026-06-3016189449core:OfficeEquipment2026-06-3016189449core:AfterOneYear2026-06-3016189449core:WithinOneYear2026-06-3016189449core:ListedExchangeTraded2026-06-3016189449core:UnlistedNon-exchangeTraded2026-06-3016189449core:ShareCapital2026-06-3016189449core:SharePremium2026-06-3016189449core:RevaluationReserve2026-06-3016189449core:OtherReservesSubtotal2026-06-3016189449core:RetainedEarningsAccumulatedLosses2026-06-3016189449core:NetGoodwill2025-01-1516189449core:IntangibleAssetsOtherThanGoodwill2025-01-1516189449core:LandBuildings2025-01-1516189449core:PlantMachinery2025-01-1516189449core:Vehicles2025-01-1516189449core:FurnitureFittings2025-01-1516189449core:OfficeEquipment2025-01-1516189449core:AfterOneYear2025-01-1516189449core:WithinOneYear2025-01-1516189449core:ListedExchangeTraded2025-01-1516189449core:UnlistedNon-exchangeTraded2025-01-1516189449core:ShareCapital2025-01-1516189449core:SharePremium2025-01-1516189449core:RevaluationReserve2025-01-1516189449core:OtherReservesSubtotal2025-01-1516189449core:RetainedEarningsAccumulatedLosses2025-01-1516189449core:NetGoodwill2025-01-1416189449core:IntangibleAssetsOtherThanGoodwill2025-01-1416189449core:LandBuildings2025-01-1416189449core:PlantMachinery2025-01-1416189449core:Vehicles2025-01-1416189449core:FurnitureFittings2025-01-1416189449core:OfficeEquipment2025-01-1416189449core:AfterOneYear2025-01-1416189449core:WithinOneYear2025-01-1416189449core:ListedExchangeTraded2025-01-1416189449core:UnlistedNon-exchangeTraded2025-01-1416189449core:ShareCapital2025-01-1416189449core:SharePremium2025-01-1416189449core:RevaluationReserve2025-01-1416189449core:OtherReservesSubtotal2025-01-1416189449core:RetainedEarningsAccumulatedLosses2025-01-1416189449core:AfterOneYear2025-01-162026-06-3016189449core:WithinOneYear2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:CostValuation2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-162026-06-3016189449core:Non-currentFinancialInstrumentscore:CostValuation2026-06-3016189449core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-06-3016189449core:Non-currentFinancialInstrumentscore:CostValuation2025-01-1516189449core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-1516189449core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-1516189449bus:Director12025-01-162026-06-3016189449core:FurnitureFittingsToolsEquipment2025-01-162026-06-3016189449core:FurnitureFittingsToolsEquipment2026-06-3016189449core:FurnitureFittingsToolsEquipment2025-01-15

TAFFS PHARMACY BRIGG LIMITED

Registered Number
16189449
(England and Wales)

Unaudited Financial Statements for the Period ended
30 June 2026

TAFFS PHARMACY BRIGG LIMITED
Company Information
for the period from 16 January 2025 to 30 June 2026

Director

HAQUE, Taffazzal

Registered Address

70 Wright Street
Hull
HU2 8JD

Registered Number

16189449 (England and Wales)
TAFFS PHARMACY BRIGG LIMITED
Balance Sheet as at
30 June 2026

Notes

2026

£

£

Fixed assets
Intangible assets3237,122
Tangible assets48,333
245,455
Current assets
Stocks512,000
Debtors20,250
Cash at bank and on hand62,125
94,375
Creditors amounts falling due within one year6(177,779)
Net current assets (liabilities)(83,404)
Total assets less current liabilities162,051
Creditors amounts falling due after one year7(173,671)
Net assets(11,620)
Capital and reserves
Called up share capital(100)
Profit and loss account(11,520)
Shareholders' funds(11,620)
The financial statements were approved and authorised for issue by the Director on 16 October 2026, and are signed on its behalf by:
HAQUE, Taffazzal
Director
Registered Company No. 16189449
TAFFS PHARMACY BRIGG LIMITED
Notes to the Financial Statements
for the period ended 30 June 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

2026
Average number of employees during the year2
3.Intangible assets

Goodwill

Total

££
Cost or valuation
Additions258,678258,678
At 30 June 26258,678258,678
Amortisation and impairment
Charge for year21,55621,556
At 30 June 2621,55621,556
Net book value
At 30 June 26237,122237,122
At 15 January 25--
4.Tangible fixed assets

Fixtures & fittings

Total

££
Cost or valuation
Additions10,00010,000
At 30 June 2610,00010,000
Depreciation and impairment
Charge for year1,6671,667
At 30 June 261,6671,667
Net book value
At 30 June 268,3338,333
At 15 January 25--
5.Stocks

2026

£
Other stocks12,000
Total12,000
6.Creditors: amounts due within one year

2026

£
Trade creditors / trade payables44,139
Bank borrowings and overdrafts26,982
Taxation and social security1,280
Other creditors105,378
Total177,779
Included within bank borrowings and overdrafts is an amount payable to the director of £27
7.Creditors: amounts due after one year

2026

£
Bank borrowings and overdrafts173,671
Total173,671
8.Related party transactions
During the year, the Company entered into transactions with related parties, being entities under common control, including Taff's Pharmacy . At the year end, amounts due from the related parties comprised £105,378 (2025: £2,280) 2026 £105,335 to Taff's Pharmacy These balances are unsecured, interest-free and repayable on demand.